The WHF forum in Switzerland
The World Heart Federation (WHF) convened a special forum May 17-18, 2023 in Geneva, Switzerland, entitled “SHINING A LIGHT ON RARE CARDIOVASCULAR DISEASES” in advance of…
Newsroom
adminlsc
-
-
Clinical trial accessible to everybody
Do you want to learn MORE about CLINICAL TRIAL? Over the past year Alnylam’s Patient Advocacy and Medical Writing teams have been collaborating to produce plain…
-
A successful therapeutic trial for Amyloidosis
A look back at a most successful therapeutic trial for Amyloidosis !We are pleased to report that the trial is very promising and paves the way…
-
What is ATTRv amyloidosis?
Amyloidosis is a group of rare diseases characterised by the abnormal deposition of amyloid proteins (proteins that misfold or twist to form “amyloid fibrils”) in various…
-
The 4th European ATTR amyloidosis meeting
The 4th European ATTR amyloidosis meeting for patients and physicians will be held on 2 and 3 November. To register, go online to the official event…
-
What is the status of amyloidosis research?
Amyloidosis is a recent disease, first described in 1838 by Rudolph Virchow, a German pathologist, who identified abnormal deposits in the tissue of deceased patients. Since…
-
Cardiac amyloidosis and transplantation
End-stage cardiac amyloidosis is an often-fatal disease that affects the ability of the heart to function properly. In recent years, heart transplantation has emerged as a…
-
First ever Canadian specific ATTR patient summit
HAC/TAC is proud to present the first-ever Canadian-specific ATTR Patient Summit An event where we will be bringing together patients, families, physicians, healthcare professionals and industry…
-
The Australian Amyloidosis Workshops: A Platform for Scientific Advancement
Amyloidosis is a group of complex, incurable diseases which are frequently misdiagnosed and under-recognised. To improve the diagnosis and management of patients with all types of…